Targeted Therapies in Cancer: To Be or Not to Be, Selective
Development of targeted therapies in recent years revealed several nonchemotherapeutic options for patients. Chief among targeted therapies is small molecule kinase inhibitors targeting key oncogenic signaling proteins. Through competitive and noncompetitive inhibition of these kinases, and therefor...
Saved in:
Main Authors: | Skye Montoya, Deborah Soong, Nina Nguyen, Maurizio Affer, Sailasya P. Munamarty, Justin Taylor |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/cfeba3ffd4da484b9306a09a2d8a6e44 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
by: Paula Aldaz, et al.
Published: (2021) -
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
by: Sareshma Sudhesh Dev, et al.
Published: (2021) -
Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
by: Florian Janisch, et al.
Published: (2021) -
Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
by: Yukari Tsubata, et al.
Published: (2021) -
Molecular targets in GI malignancies – A pathologist's perspective
by: Satyajit Pawar, et al.
Published: (2021)